This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
The thirty-nine reports contained in this volume range in subject from records of drugs cast on the therapeutic scrap heap to statements on the names and uses of latest additions to the physician's armamentarium. Among the discontinued are two proprietary drugs, Isacen and Melubrin: Isacen was accepted in 1926 as a nontoxic laxative or purgative; Melubrin is an antipyretic which seemed to have promise when it was accepted in 1913 but which the manufacturer has now ceased marketing. At the time these preparations were accepted the Council expressed some misgivings which later proved justified.
Among the reports on nomenclature are those designating "pyridoxine" and "pyridoxine hydrochloride" for vitamin B6 and vitamin B6 hydrochloride, "sulfathiazole" for 2-sulfanilamidothiazole and "sulfamethylthiazole" for 2-sulfanilamido-4-methylthiazole. Preliminary reports on these drugs as well as on phenothiazine and histaminase are included.
Other noteworthy preliminary reports are on guanidine hydrochloride-Calco, which has been proposed for use
Annual Reprint of the Reports of the Council on Pharmacy and Chemistry of the American Medical Association for 1940 with the Comments That Have Appeared in The Journal. JAMA. 1941;117(15):1303. doi:10.1001/jama.1941.02820410081038
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: